Patents Represented by Attorney Roy D. Meredith
  • Patent number: 5449830
    Abstract: A regioselective processes are disclosed for the synthesis of (1R,1S)-amino-(2S,2R)-alkanol, particularly (1R,1S)-amino-(2S,2R)-indanol.
    Type: Grant
    Filed: March 11, 1994
    Date of Patent: September 12, 1995
    Assignee: Marck & Co., Inc.
    Inventors: Thomas R. Verhoeven, Edward F. Roberts, Chris H. Senanayake, Kenneth M. Ryan
  • Patent number: 5436131
    Abstract: A chromogenic assay is described for the identification and isolation of drug-resistant HIV protease mutants. Coversely, the assay is useful to screen for new inhibitors of HIV protease, e.g., inhibitors not affected by drug-resistance of the HIV protease. This color screening assay contains a vector comprising a regulatable promoter which controls the transcription of two adjacent structural sequences, one sequence coding for HIV protease or mutant thereof, the other sequence coding for beta-galactosidase with an amino acid substrate insert cleavable by HIV protease. A library of HIV proteases is also described and is isolated in the form of a collection of such vectors, which is a color screen vector library.
    Type: Grant
    Filed: April 2, 1993
    Date of Patent: July 25, 1995
    Assignee: Merck & Co., Inc.
    Inventors: Jon H. Condra, Donald J. Graham, Leah Gotlib
  • Patent number: 5434152
    Abstract: An asymmetric synthesis of (S)-(-)-6-chloro-4-cyclopropyl-3,4-dihydro-4-[(2-pyridyl)ethynyl]-2(1H)-qu inazolinone comprises the chiral addition of 2-pyridylacetylide to N.sup.1 -protected 6-chloro-4-cyclopropyl-2-quinazolinone followed by removal of the protecting group.
    Type: Grant
    Filed: November 8, 1993
    Date of Patent: July 18, 1995
    Assignee: Merck & Co., Inc.
    Inventors: Mark A. Huffman, Nobuyoshi Yasuda, Ann E. DeCamp, Edward J. J. Grabowski
  • Patent number: 5426230
    Abstract: 4-Chloro-2-cyclopropylcarbonylaniline is prepared by condensation of 4-chloroaniline with 4-chlorobutyronitrile to form a 2-(4-chlorobutyryl)-4-chloroaniline, followed by ring closure of the 4-chlorobutyryl group to a cyclopropylcarbonyl moiety.
    Type: Grant
    Filed: June 10, 1994
    Date of Patent: June 20, 1995
    Assignee: Merck & Co., Inc.
    Inventors: Alan Douglas, Ioannis Houpis, Audrey Molina, Ralph P. Volante, Nobuyoshi Yasuda
  • Patent number: 5420353
    Abstract: A regioselective process is disclosed for synthesis of 1R-amino-2S-indanol or 1S-amino-2R-indanol, wherein the stereochemical integrity of the carbon-oxygen bond at C-2 in the indene oxide starting material is retained.
    Type: Grant
    Filed: March 11, 1994
    Date of Patent: May 30, 1995
    Assignee: Merck & Co., Inc.
    Inventors: Thomas R. Verhoeven, F. Edward Roberts, Christ H. Senanayake, Kenneth M. Ryan
  • Patent number: 5413999
    Abstract: Compounds of formula ##STR1## where R.sup.1 and R.sup.2 are independently hydrogen or optionally-substituted C.sub.1-4 alkyl or aryl, or R.sup.1 and R.sup.2 are joined together to form a monocyclic or bicyclic ring system, are HIV protease inhibitors. These compounds are useful in the treatment of infection by HIV and in the treatment of AIDS, either as compounds, pharmaceutically acceptable salts, pharmaceutical composition ingredients, whether or not in combination with other antivirals, immunomodulators, antibiotics or vaccines. Methods of treating AIDS and methods of treating infection by HIV are also described.
    Type: Grant
    Filed: May 7, 1993
    Date of Patent: May 9, 1995
    Assignee: Merck & Co., Inc.
    Inventors: Joseph P. Vacca, Bruce D. Dorsey, James P. Guare, M. Katharine Holloway, Randall W. Hungate, Rhonda B. Levin
  • Patent number: 5387512
    Abstract: Incubation of ##STR1## with a preparation from mammalian organ yields as biotransformation product the compound 3-[2-(benzoxazol-2-yl)ethyl]-5-(1-hydroxyethyl)-6-methyl-2-(1H)-pyridinone . This product is useful in the prevention or treatment of infection by HIV and the treatment of AIDS.
    Type: Grant
    Filed: February 24, 1992
    Date of Patent: February 7, 1995
    Assignee: Merck & Co. Inc.
    Inventors: Suresh K. Balani, Steven M. Pitzenberger, Harri G. Ramjit
  • Patent number: 5380849
    Abstract: A process for preparing optically pure decahydroisoquinolines in good yields which avoids difficult purification procedures is described.
    Type: Grant
    Filed: November 9, 1992
    Date of Patent: January 10, 1995
    Assignee: Merck & Co., Inc.
    Inventors: Ioannis N. Houpis, Joseph E. Lynch, Audrey Molina, Ralph P. Volante
  • Patent number: 5364776
    Abstract: Incubation of ##STR1## with a preparation from mammalian organ yields as biotransformation products the 5-(1-hydroxy)ethyl pyridinone analog as well as the 5-(1-hydroxy)ethyl pyridyl and the 5-(2-hydroxy)ethyl pyridyl derivatives.
    Type: Grant
    Filed: February 24, 1992
    Date of Patent: November 15, 1994
    Assignee: Merck & Co., Inc.
    Inventors: Suresh K. Balani, Laura R. Kauffman, Anthony D. Theoharides
  • Patent number: 5322855
    Abstract: Zaragozic acids isolated from a culture of MF5465 have been subjected to photoreaction, then derivatized at the 4-keto position. The resulting derivatives are active as squalene synthetase inhibitors and are useful in the treatment of hypercholesterolemia.
    Type: Grant
    Filed: November 24, 1992
    Date of Patent: June 21, 1994
    Assignee: Merck & Co., Inc.
    Inventors: Laszlo R. Treiber, Doss, George A., Byron H. Arison
  • Patent number: 5317031
    Abstract: Cholesterol lowering compounds and compositions are formed from the photochemical treatment of the Zaragozic Acids followed by esterification. These compounds and compositions are active squalene synthetase inhibitors useful in the treatment of hypercholesterolemia.
    Type: Grant
    Filed: November 24, 1992
    Date of Patent: May 31, 1994
    Assignee: Merck & Co., Inc.
    Inventors: John G. MacConnell, Byron H. Arison, George A. Doss, Richard L. Monaghan
  • Patent number: 5310949
    Abstract: New Zaragozic acids have been isolated from a culture of MF5465. These compounds and their derivatives are active as squalene synthetase inhibitors and are useful in the treatment of hypercholesterolemia.
    Type: Grant
    Filed: September 2, 1992
    Date of Patent: May 10, 1994
    Assignee: Merck & Co., Inc.
    Inventors: Claude Dufresne, Prakash S. Masurekar, Leslie A. Ferrell, Deborah L. Zink, Margaret S. Sosa
  • Patent number: 5308854
    Abstract: Novel aminopyridones inhibit HIV reverse transcriptase, and are useful in the prevention or treatment of infection by HIV and the treatment of AIDS, either as compounds, pharmaceutically acceptable salts, pharmaceutical composition ingredients, whether or not in combination with other antivirals, anti-infectives, immunomodulators, antibiotics or vaccines. Methods of treating AIDS and methods of preventing or treating infection by HIV are also described.
    Type: Grant
    Filed: November 4, 1992
    Date of Patent: May 3, 1994
    Assignee: Merck & Co., Inc.
    Inventors: Jacob M. Hoffman, Jr., Walfred S. Saari, Clarence S. Rooney, John S. Wai
  • Patent number: 5290941
    Abstract: An efficient process for the preparation of styrylbenzoxazoles and derivatives thereof comprises reacting a methylbenzoxazole with an aromatic aldehyde in the presence of strong base at low temperature, followed by warming. The condensation products are inhibitors of H.sup.+ K.sup.+ -ATPase, and are also useful as penultimate compounds in the preparation of inhibitors of HIV reverse transcriptase.
    Type: Grant
    Filed: October 14, 1992
    Date of Patent: March 1, 1994
    Assignee: Merck & Co., Inc.
    Inventors: Ralph P. Volante, Joseph E. Lynch, Ioannis Houpis, Audrey Molina
  • Patent number: 5250563
    Abstract: Novel cytochalasins are the biotransformed products after incubation with a substrate in a culture of the microorganism Kibdelosporangium sp. (Merck Culture Collection MA 6559), ATCC No. 53771. The compounds of the present invention inhibit HIV protease and are useful in the prevention or treatment of infection by HIV and the treatment of AIDS, either as a compound, pharmaceutically acceptable salt, pharmaceutical composition ingredient, whether or not as a prodrug or as a combination with other antivirals, anti-infectives, immunomodulators, antibiotics or vaccines.
    Type: Grant
    Filed: September 25, 1992
    Date of Patent: October 5, 1993
    Assignee: Merck & Co., Inc.
    Inventors: Shieh-Shung T. Chen, George A. Doss, Russell B. Lingham
  • Patent number: 5215900
    Abstract: Fermentation of the microorganism Streptomyces sp. (MA6804), ATTC No. 55095, in the presence of the HIV reverse transcriptase inhibitor ##STR1## yields a 5-(1-hydroxy)ethyl analog which is useful in the prevention or treatment of infection by HIV and the treatment of AIDS.
    Type: Grant
    Filed: June 7, 1991
    Date of Patent: June 1, 1993
    Assignee: Merck & Co., Inc.
    Inventors: Shieh-Shung T. Chen, George Doss
  • Patent number: 5202243
    Abstract: Incubation of 3-[2-benzoxazol-2-yl)ethyl]-5-ethyl-6-methyl-2-(1H)-pyridinone ##STR1## with a preparation from mammalian organ yields as biotransformation product the 6-hydroxymethyl analog. This product is useful in the prevention or treatment of infection by HIV and the treatment of AIDS.
    Type: Grant
    Filed: March 16, 1992
    Date of Patent: April 13, 1993
    Assignee: Merck & Co., Inc.
    Inventor: Suresh K. Balani
  • Patent number: 5200329
    Abstract: Incubation of 3-[(4,7-dichlorobenzoxazol-2-yl)methyl]amino-5-ethyl-6-methyl-2-(1H)-pyrid inone ##STR1## with a preparation from mammalian organ yields as biotransformation products the 5-(1-hydroxy)ethyl and 6-hydroxymethyl analogs. These products are useful in the prevention or treatment of infection by HIV and the treatment of AIDS.
    Type: Grant
    Filed: March 10, 1992
    Date of Patent: April 6, 1993
    Assignee: Merck & Co., Inc.
    Inventors: Suresh K. Balani, Anthony D. Theoharides, Laura R. Kauffman
  • Patent number: 5192668
    Abstract: A dipeptide isostere is the biotransformed product after incubation with a culture of Streptomyces. It inhibits HIV protease, and is useful in the prevention or treatment of infection by HIV and the treatment of AIDS, either as a compound, pharmaceutically acceptable salt, pharmaceutical composition ingredient, whether or not as a prodrug or as a combination with other antivirals, anti-infectives, immunomodulators, antibiotics or vaccines. Methods of treating AIDS and methods of preventing or treating infection by HIV are also described.
    Type: Grant
    Filed: February 27, 1992
    Date of Patent: March 9, 1993
    Assignee: Merck & Co., Inc.
    Inventors: Laszlo R. Treiber, Lawrence F. Colwell, Jr., Byron H. Arison, Georgette Dezeny, Russell B. Lingham, Wayne J. Thompson, Suresh K. Balani
  • Patent number: 5188950
    Abstract: Novel dipeptide isosteres are the biotransformed products after incubation with rat liver slices. They inhibit HIV protease, and are useful in the prevention or treatment of infection by HIV and the treatment of AIDS, either as compounds, pharmaceutically acceptable salts (when appropriate), pharmaceutical composition ingredients, whether or not in combination with other antivirals, anti-infectives, immunomodulators, antibiotics or vaccines. Methods of treating AIDS and methods of preventing or treating infection by HIV are also described.
    Type: Grant
    Filed: February 27, 1992
    Date of Patent: February 23, 1993
    Assignee: Merck & Co., Inc.
    Inventors: Suresh K. Balani, Harri G. Ramjit, Steven M. Pitzenberger, Michael S. Schwartz, Anthony Y. H. Lu